1381928-19-3

Basic information

• Product Name: (R)-5-Fluoro-2,3-dihydro-1H-inden-1-aMine hydrochloride
• Synonyms: (R)-5-Fluoro-2,3-dihydro-1H-inden-1-aMine hydrochloride;-5-Fluoro-2,3-dihydro-1H-inden-1-amine hydrochloride;(R)-5-FLUORO-2,3-DIHYDRO-1H-INDEN-1-AMINE HYDROCHLRIDE
• CAS NO: 1381928-19-3
• Molecular Formula: C9H11ClFN
• Molecular Weight: 187.6417432
• Mol File: 1381928-19-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: (R)-5-Fluoro-2,3-dihydro-1H-inden-1-aMine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-5-Fluoro-2,3-dihydro-1H-inden-1-aMine hydrochloride(1381928-19-3)
• EPA Substance Registry System: (R)-5-Fluoro-2,3-dihydro-1H-inden-1-aMine hydrochloride(1381928-19-3)

Safety Data

• Hazardous Substances Data: 1381928-19-3(Hazardous Substances Data)

Usage

General Description

The chemical (R)-5-Fluoro-2,3-dihydro-1H-inden-1-aMine hydrochloride is a compound used in research and development as a potential pharmaceutical ingredient. It is a derivative of the neurotransmitter dopamine and has been studied for its potential effects on the central nervous system. It is a crystalline solid that is typically used in its hydrochloride form for ease of handling and storage. Its molecular structure consists of a fluorine atom attached to a dihydroindene ring, with an amine group and an (R)-stereocenter. (R)-5-Fluoro-2,3-dihydro-1H-inden-1-aMine hydrochloride is of interest for its potential pharmacological properties and may have applications in the development of new therapeutic drugs.

Upstream product

• 101752-05-0 methanol hydrochloride 
• 700-84-5 5-fluoro-1-indanone 
• 148960-32-1 5-fluoro-1-indanone oxime 

Relevant articles and documents

CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.

alpha-SUBSTITUTED GLYCINAMIDE DERIVATIVE

The present invention is to provide a novel α-substituted glycinamide derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. The present invention provides a compound represented by the general formula (I), which has TRPM8 inhibitory effects: [wherein A1 represents a C6-10 aryl and the like, A2 represents a C6-10 aryl and the like, X represents CH and the like, Y represents —CR1R2— and the like, R1 and R2 independently represent a hydrogen atom and the like, R3 and R4 independently represent a halogen atom and the like, n is 1 or 2], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing diseases or symptoms caused by hyperexcitability or disorder of afferent neurons.

NOVEL TRPM8 INHIBITOR

PROBLEM TO BE SOLVED: To provide a novel α-substituted glycine amide derivative, or a pharmaceutical composition containing pharmacologically acceptable salt thereof, and a medicinal use thereof. SOLUTION: The present invention provides a compound expressed by a general formula (I) having TRPM8 inhibitory action (in the formula, A1 denotes C6-10 aryl or the like, A2 denotes C6-10 aryl or the like, X denotes CH or the like, Y denotes -CR1R2- or the like, R1 and R2 denote hydrogen atom or the like independently, R3 and R4 denote halogen atom or the like independently, and n denotes 1 or 2), or a pharmaceutical composition containing pharmacologically acceptable salt thereof. Furthermore, a pharmaceutical composition of the present invention is usable as treatment or a prophylactic drug of disease or symptom caused by hyperexcitement or disorder of afferent nerves. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT